Kozak & Associates’s DexCom DXCM Stock Holding History

Kozak & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1	Closed	-$87	–	448
2024 Q3	$87	Hold	1	–	–	﹤0.01%	378
2024 Q2	$138	Hold	1	–	–	﹤0.01%	372
2024 Q1	$165	Buy	+1	New	+$126	﹤0.01%	373

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Kozak & Associates's DXCM Position: Q4 2024 in Review

Kozak & Associates sold out of DexCom (DXCM) in Q4 2024, closing a stake of 1 share — an estimated $87 sold.

Kozak & Associates first reported a position in DXCM in Q1 2024 and held it in 3 quarters. The position peaked at $165 in Q1 2024. 950 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

Kozak & Associates reported no remaining DexCom position as of Q4 2024 after selling out during the quarter.
Kozak & Associates sold 1 DexCom share in Q4 2024, an estimated $87.
Kozak & Associates first reported a position in DexCom in Q1 2024 and held it in 3 quarters.
Kozak & Associates's DexCom position peaked at $165 in Q1 2024.
950 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on Kozak & Associates's 13F filing for Q4 2024, filed 6 Jan 2025.